Severe hepatitis associated with tocilizumab in a patient with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 52, Issue 7, 2013, Pages 1340-1341

  Alfreijat, Majd ^a   Habibi, Mohammadali ^a   Bhatia, Primaljyot ^b   Bhatia, Abhijit ^a  

^a UNION MEMORIAL HOSPITAL   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ESOMEPRAZOLE; INFLIXIMAB; METFORMIN; METHOTREXATE; METHYLPREDNISOLONE; PANCREAS ENZYME; PREDNISONE; PREGABALIN; ROSUVASTATIN; TOCILIZUMAB;

ACUTE HEPATITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHOLESTASIS; HUMAN; HYPERTRANSAMINASEMIA; JAUNDICE; LETTER; LIVER BIOPSY; LIVER CELL; LIVER CELL DAMAGE; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; TOXIC HEPATITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BIOPSY; DRUG-INDUCED LIVER INJURY; HUMANS; MALE; MIDDLE AGED;

EID: 84879814164     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes397     Document Type: Letter

References (6)

1. Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm 2008;15:1413-8.
2. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: results from a 24-week multicentre randomized placebo-controlled trial. Ann Rheum Dis 2008;11:1516-23.
3. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011;3:552-62.
4. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;3: 222-32.
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther 1981;2:239-45.
6. Gallagher RM, Kirkham JJ, Mason JR, et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS One 2011;6: e28096.